Xuanyu Medical Secures Nearly RMB 100 Million in Series A+ Financing to Accelerate Commercialization of Cardiac Electrophysiology and Peripheral Vascular Intervention Products

VCBeat learned第一时间 that ShineyoMedical, a provider专注于心脏电生理与外周血管介入治疗方案, recently announced the completion ofNearly 100 Million Yuan in Series A+ RoundFinancing, this round of financing was led byGuangzhou Jinkong Fund Management co.,Ltd. leads the investment, Suzhou Zhuopu Investment Fund Management Co., Ltd, and Jinxin CapitalAndZhangjiagang Industrial CapitalJointly participated by multiple investment institutions, including existing shareholdersIndustrial CapitalContinuous support.

This round of funding will mainly be used for the construction of the company's commercialization team, acceleration of production base operations, and R&D of product pipelines, creating a differentiated portfolio of cardiac electrophysiology and peripheral vascular intervention products.

ShineyoMedical was established in May 2020 in the Zhangjiang High-Tech Zone of the China (Shanghai) Pilot Free Trade Zone. Relying on three major technology development platforms—active devices, interventional catheters, and biomaterials—the company has entered two significant fields: cardiac electrophysiology and peripheral interventions. It aims to become a leading innovator in the minimally invasive interventional medical device industry for electrophysiology and peripheral vascular applications, providing doctors and patients with cutting-edge, accessible, and innovative clinical solutions.

Since its establishment four years ago, ShineyoMedical has independently developed innovative products in cardiac electrophysiology and peripheral vascular intervention, such as the cardiac pulsed field ablation system (PFA) and venous closure system.The registration applications for related products were officially accepted by NMPA in the first half of 2024 and are expected to enter the commercial validation phase by the end of 2024.

In April 2024, ShineyoMedical's self-developed VariSeal^®ShineyoMedical's Vein Closure System Won the Second Prize in VINNOVA's 2nd Innovation Competition.

ShineyoMedical's self-developed VariSeal^®ShineyoMedical's Venous Closure System Wins Second Prize in VINNOVA's 2nd Innovation Competition

VariSeal^®The venous closure system is an innovative therapy for varicose vein treatment.Composed of an adhesive and a delivery system. The adhesive solidifies from liquid upon contact with anions in the human body through an anionic polymerization mechanism, achieving vascular adhesion; the delivery system consists of a dispensing gun and an injection catheter, establishing the adhesive pathway with the cooperation of a guidewire and a long sheath. The adhesive is injected into the target vessel under the joint guidance of the injection catheter and red light.

Particularly impressive is the system's unique red light design, with visible red light on the body surface acting like a "guiding light" during surgery, providing the surgeon with intuitive and clear navigation. The design of the dispensing gun is equally ingenious, capable of achieving precise micro-injections as small as 0.1ml. The combination of fiber optic navigation and precise injection can achieve the clinical goal of accurately sealing superficial veins in the lower limbs.

Currently, VariSeal^®The venous closure system product has successfully completed clinical trial follow-ups, and the registration materials have been submitted.

VariSeal^®Venous Closure System

Rhythpulse^®Multi-channel Cardiac Pulsed Field Ablation SystemIs another flagship product of ShineyoMedical, which entered the NMPA Innovative Medical Device Special Review in March 2023. The product consists of a multi-channel cardiac pulse field ablation generator and a cardiac pulse ablation catheter, and is compatible with mainstream 3D cardiac electrophysiology mapping systems. It is mainly used for the treatment of rapid arrhythmias. By precisely delivering high-voltage pulses to myocardial tissue, it induces irreversible electroporation in the target myocardial cells, thereby permanently isolating abnormal electrical signal conduction, restoring normal sinus rhythm, and achieving therapeutic goals.

ShineyoMedical's multi-channel pulsed electric field ablation instrument can deliver pulse energy either individually or in combination, and is equipped with an ECG gating function that senses the refractory period for discharge to prevent ventricular fibrillation. The device offers diverse discharge modes during treatment to enable precise ablation of the target area.

At the same time, the specifications of the cardiac pulsed field ablation catheter can cover the full-size pulmonary vein vestibule area. The unique small loop diameter (10mm) catheter enables localized large focal contact ablation. The proprietary patented asymmetrical ablation electrode design improves ablation efficiency, reduces ineffective discharge of electrodes in the blood, avoids hemolysis-related renal function damage, and achieves targeted ablation effects.

Currently, the product has completed clinical enrollment trials and a one-year follow-up, and submitted registration materials in the first half of the year.

Rhythpulse® Multi-Channel Cardiac Pulsed Field Ablation System

For obtaining this round of financing,ShineyoMedical Founder Chen ShuguoStated: We are grateful for the support and recognition from this round of investment institutions and existing shareholders. This round of financing occurs as we are in the process of submitting multiple products for registration and initiating commercial operations. It is a great honor to receive investors' support during the current capital winter. The ShineyoMedical team will continue to work tirelessly, accelerating the launch of our products to market to benefit more patients as soon as possible.

NIE Huiming, Head of Biomedical Investment at Guangzhou Jinkong Fund Management Co., Ltd.The investment institutions representing this round of financing stated: The founding team of ShineyoMedical has a diverse background and can accurately grasp the industry development trends and changes in the cardiovascular field. In addition, ShineyoMedical's general technology platform can continuously innovate in product design concepts, enriching the product portfolio and commercialization implementation. We are optimistic about ShineyoMedical’s founding team, technical reserves, and product layout, and believe that ShineyoMedical will continue to lead the industry with its technological innovation capabilities, benefiting a wide range of patients. Guangzhou Jinkong Fund Management Co., Ltd. will firmly support the development of the biopharmaceuticals industry and the process of innovative medical product research, development, and market launch.

Guangzhou Financial Holdings Group Co., Ltd. is a state-owned financial holding platform established by the Guangzhou Municipal Committee and Municipal Government to integrate municipal financial assets. It has become the largest local financial holding group in China in terms of asset scale, with the highest credit rating and the most complete range of financial licenses. It serves as an important booster for achieving high-quality economic development in Guangzhou. As of the end of June 2023, the group's total assets amounted to 881.864 billion yuan. It received international ratings of A- from Fitch and BBB+ from Standard & Poor's, the highest credit ratings among local financial holding groups in China, and ranked 258th in the top 500 service enterprises in China in 2023.

Suzhou Zhuopu Investment Fund Management Co., Ltd. was established in 2018 as a wholly-owned subsidiary of Suzhou Asset Management Co., Ltd. It has long been dedicated to fields such as next-generation information technology, aerospace, semiconductors, biomedicine, and artificial intelligence, with a management scale exceeding 2 billion yuan. Zhuopu Capital actively manages multiple direct investment funds, including Zhuopu No. 1 Fund, Gusu Talent Phase II Fund, Zhangjiagang Talent No. 1 Fund, Zhuopu Yongying Fund, and Zhuoyun Qihang Fund, focusing on four major leading industries in Suzhou: electronic information, high-end equipment, advanced materials, and new energy.

Industrial Capital Management Co., Ltd. was established in 2010 as a wholly-owned private equity investment fund subsidiary of Industrial Securities Co., Ltd. (SH601377). It has cumulatively managed and serviced funds with a total scale exceeding tens of billions of yuan. Industrial Capital is committed to combining its own equity investment experience with the platform advantages of a securities firm subsidiary to provide multi-faceted post-investment value-added services for invested enterprises. Together with the invested companies, it aims to grow healthily, develop sustainably, and progress from excellence to eminence.

Zhangjiagang Shazhou Sci-Tech Innovation Fund, jointly established by the Zhangjiagang Science and Technology Bureau and Zhangjiagang Innovative Investment Group, adopts a direct investment strategy. The fund focuses on emerging industrial chain projects such as specialty semiconductors, biomedicine and high-end medical devices, new energy, and the digital economy. Among these, healthcare and high-end medical devices are also key areas of focus for the fund. By attracting a group of potential high-quality projects with high levels of industrialization, market recognition, and technological content, the fund aims to bring "fresh momentum" to Zhangjiagang's industrial development and promote industrial transformation and upgrading.

Zhangjiagang Jinxin Capital Investment Management Co., Ltd. is a wholly state-owned company依托于江苏扬子江国际冶金工业园, mainly engaged in equity investment and investment management businesses. Jinxin Capital focuses on the development of the "3+N" industrial cluster in the industrial park and town, creating an information window for industrial capital in the park and town, actively playing the role of capital allocation, flexibly utilizing various investment methods to guide social capital investment into the park and town industries, promoting internal and external circulation, channeling resources, and strengthening industrial chains through investment. It advances the enhancement, supplementation, extension, and strengthening of the industrial chains in the park and town, adopting a dual approach of bringing in and going global, leading state-owned capital and enterprises in the park and town towards broader horizons.